tuning
the immune
system
Small molecules that separate a vaccine’s side effects from how well it works.
Both move together. Dose is capped by tolerability.
Inflammation comes down. Immune response is enhanced.
For thirty years immunology has worked with one lever.
Turn the immune response up and the inflammation comes up with it. The two have stayed tied together because the field has been adjusting how hard a receptor is hit, not what happens after it is hit.
The result is a ceiling. Dose is capped by how much reactogenicity a person will tolerate rather than by how much protection is available. Whole programs are shaped by that limit.
Signl adds channels.
Our small molecules act on central nodes of innate immune signaling rather than on receptor binding. The inflammatory arm of a response and the protective arm can be set separately.
It goes into what you already run.
The molecules co-formulate with vaccines and delivery systems that already exist. They can be used across antigens and vaccine types.
Out of the University of Chicago.
Signl was founded on research from the University of Chicago by Aaron Esser-Kahn and Jeremiah Kim. The company is based at the University of Chicago Science Incubator.
Program specifics are shared under confidentiality.
